EDINBURGH, Scotland--(BUSINESS WIRE)--IOmet Pharma, a privately-held company focused on cancer immunotherapy and cancer metabolism, will present data demonstrating superior properties of its novel, pre-clinical IDO1, TDO and IDO1/TDO Dual Inhibitor programs. The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia on April 22.
Help employers find you! Check out all the jobs and post your resume.
